AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8070927
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg fluconazole for 10-21 days
Trial: 8070927
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg fluconazole
Trial: 3281775
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg inhaled diltiazem
Trial: 3281775
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg inhaled diltiazem
Trial: 3281775
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg inhaled diltiazem
Trial: 3281775
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg inhaled diltiazem
Trial: 3281775
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg inhaled diltiazem
Trial: 3281775
Drug: High-dose diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose diltiazem (20 to 45 mg)
Trial: 27692976
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg once daily for 5 days
Trial: 25608582
Drug: Deep breathing
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep breathing test (DBT) + sequential standard BP measurement
Trial: 25608582
Drug: Sequential standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential standard BP measurement only
Trial: 23312003
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity Internet-delivered psychotherapy + improved treatment as usual (ITAU) by GP
Trial: 21658716
Drug: Miglustat treatment
RxNorm normalized name: Miglustat
DrugBank: Miglustat (DB00419)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Miglustat treatment
Trial: 24276460
Drug: Odanacatib 50
RxNorm normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odanacatib 50 mg once weekly
Trial: 15688961
Drug: Toothbrush without
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Toothbrush without antimicrobial agent (control)
Trial: 9567620
Drug: Rokitamycin 800
RxNorm normalized name: rokitamycin
DrugBank: Rokitamycin (DB13409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rokitamycin 800 mg/day
Trial: 9567620
Drug: Rokitamycin 1200
RxNorm normalized name: rokitamycin
DrugBank: Rokitamycin (DB13409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rokitamycin 1200 mg/day
Trial: 8205303
Drug: Nitrendipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (10 mg/day)
Trial: 3360340
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injection to the antagonist, nonparalytic horizontal rectus muscle
Trial: 3360340
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no botulinum toxin treatment)
Trial: 31958877
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive pills (COCP) containing 20 mcg ethinyl estradiol/150 mg desogestrel for two continuous cycles
Trial: 31958877
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs (NSAID); mefenamic acid 500 mg TDS for 5 days, 21 days apart for two cycles
Trial: 27871076
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg daily for 1 week pre-URS
Trial: 25632646
Drug: Oral ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ivermectin 200 sg/kg body weight
Trial: 25632646
Drug: Topical lindane
RxNorm normalized name: lindane Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lindane lotion 1% (two applications with a 1-week interval)
Trial: 21511828
Drug: Pirfenidone 1200
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone 1200 mg/d
Trial: 21511828
Drug: Pirfenidone 2400
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone 2400 mg/d
Trial: 20598667
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg intravitreal ranibizumab
Trial: 20598667
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg intravitreal ranibizumab
Trial: 12014437
Drug: Non-Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-Hormone Replacement Therapy (non-HRT)
Trial: 20533545
Drug: Abatacept (∼10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept (∼10 mg/kg of body weight)
Trial: 9477021
Drug: Full-mouth disinfection
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-mouth disinfection (scaling and rootplaning of all pockets in 2 visits within 24 h, tongue brushing with 1% chlorhexidine gel for 1 min, mouth rinsing with 0.2% chlorhexidine solution for 2 min, subgingival irrigation of all pockets with 1% chlorhexidine gel 3x in 10 min, rinsing 2x daily with 0.2% chlorhexidine, spraying tonsils with 0.2% chlorhexidine for 2 months)
Trial: 9477021
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (scaling and rootplaning per quadrant at 2-week intervals, oral hygiene instructions)
Trial: 27606616
Drug: Körpertambura treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Körpertambura treatment (10-minute session)
Trial: 20479425
Drug: Cisplatin (CIS)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CIS) 100 mg/m(2) on day 1 of weeks 1, 4, and 7
Trial: 20479425
Drug: Cisplatin (CIS)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CIS) 75 mg/m(2) plus Tirapazamine (TPZ) 290 mg/m(2)/d on day 1 of weeks 1, 4, and 7 and TPZ alone 160 mg/m(2)/d on days 1, 3, and 5 of weeks 2 and 3 (TPZ/CIS)
Trial: 18410547
Drug: LT4-LT3 combination
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LT4-LT3 combination therapy
Trial: 15634723
Drug: Oral vitamin-B
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral vitamin-B and folic acid therapy (n = 27)
Trial: 12879814
Drug: Spiron (local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiron (local formulation of risperidone)
Trial: 12879814
Drug: Risperdal (original
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperdal (original formulation of risperidone)
Trial: 2651174
Drug: Tenoxicam 20
RxNorm normalized name: tenoxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 20 mg/day
Trial: 3905218
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg/day
Trial: 28332859
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (2 mL) in 2 mL normal saline
Trial: 8922004
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (4 mL)
Trial: 22957434
Drug: Osmotic pump
RxNorm normalized name: Ez2go Osmotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osmotic pump tablets with EC/PVP K30
Trial: 17564561
Drug: Cockcroft-Gault (C-G)
RxNorm normalized name: Gaultheria procumbens top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cockcroft-Gault (C-G)
Trial: 7840507
Drug: Adjuvant tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant tamoxifen 20 mg once daily for two years
Trial: 2849717
Drug: Acyclovir (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (500 mg/m² IV every 8 hours for 7 days, followed by 800 mg orally four times daily for 30 days)
Trial: 2849717
Drug: Placebo (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenous placebo for 7 days, followed by oral placebo for 30 days)
Trial: 1498372
Drug: Topical khellin
RxNorm normalized name: khellin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical khellin (2% solution in acetone and propylene glycol) plus sunlight exposure for 4 months with 3 weekly applications and exposure times up to 90 min.
Trial: 1498372
Drug: Placebo (acetone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (acetone and propylene glycol) plus sunlight exposure for 4 months with 3 weekly applications and exposure times up to 90 min.
Trial: 710312
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin (3 X 5000 IU/24 h)
Trial: 902597
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (3.6 g daily)
Trial: 30324251
Drug: Drug-induced movement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-induced movement disorders
Trial: 21844490
Drug: Telemonitoring and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemonitoring and study physician medication management
Trial: 9635648
Drug: Protocol group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol group (DO2 > or =600 mL/min/m2)
Trial: 3341317
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (975 mg/d)
Trial: 21798642
Drug: USB-PRP combination
RxNorm normalized name: HEMOPHILUS B PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USB-PRP combination
Trial: 16959690
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no additional hemostatic treatment)
Trial: 3139428
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg sublingual nitroglycerin (Nitromex)
Trial: 3139428
Drug: 0.50 mg
RxNorm normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 mg sublingual nitroglycerin (Nitromex)
Trial: 3139428
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg sublingual nitroglycerin (Nitromex)
Trial: 3139428
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg sublingual nitroglycerin (Nitromex)
Trial: 3139428
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ordinary nitroglycerin
Trial: 31387119
Drug: Low fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fish oil (LFO) group (20% LC n‐3 PUFAs, 0.5 g/d)
Trial: 31387119
Drug: High fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fish oil (HFO) group (60% LC n‐3 PUFAs, 2.0 g/d)
Trial: 31387119
Drug: Control (CON)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (CON) group (0% LC n‐3 PUFAs, 0 g/d)
Trial: 27225617
Drug: Oral dose
RxNorm normalized name: Exactamed Oral Dose Syringe 35cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of 50,000 IU vitamin D3 every week for 8 weeks, followed by 1 pearl every 2 weeks for 4 weeks (total of 3 months)
Trial: 27225617
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no vitamin D treatment)
Trial: 25438724
Drug: Encenicline 1
RxNorm normalized name: Encenicline
DrugBank: Encenicline (DB11726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encenicline 1 mg oral capsule
Trial: 25438724
Drug: Encenicline 1
RxNorm normalized name: Encenicline
DrugBank: Encenicline (DB11726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encenicline 1 mg oral solution
Trial: 25438724
Drug: Encenicline 20
RxNorm normalized name: Encenicline
DrugBank: Encenicline (DB11726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encenicline 20 mg dose
Trial: 25438724
Drug: Encenicline 1-180
RxNorm normalized name: Encenicline
DrugBank: Encenicline (DB11726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encenicline 1-180 mg doses
Trial: 25438724
Drug: Encenicline (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encenicline (various doses)
Trial: 25438724
Drug: Encenicline (1-180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encenicline (1-180 mg)
Trial: 21704313
Drug: Percutaneous E(2)
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous E(2) (100 μg/24 h) during 2 weeks perimenstrually
Trial: 15112179
Drug: Doxercalciferol treatment
RxNorm normalized name: Doxercalciferol
DrugBank: Doxercalciferol (DB06410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxercalciferol treatment
Trial: 15112179
Drug: Doxercalciferol treatment
RxNorm normalized name: Doxercalciferol
DrugBank: Doxercalciferol (DB06410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxercalciferol treatment and Placebo
Trial: 10778998
Drug: Antiplatelet treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet treatment with ticlopidine (Group B)
Trial: 10778998
Drug: Anticoagulant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant treatment with acenocoumarol (Group A)
Trial: 9323513
Drug: L-Dopa treatment
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-Dopa treatment (ON)
Trial: 9323513
Drug: OFF L-Dopa
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OFF L-Dopa
Trial: 31080168
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept 2 mg every 8 weeks for 52 weeks, after 5 initial doses every 4 weeks.
Trial: 30103252
Drug: Subcutaneous dalteparin
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous dalteparin
Trial: 30284557
Drug: Subcutaneous dalteparin
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous dalteparin (in Select-D study)
Trial: 23807272
Drug: MRKAd5 HIV‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRKAd5 HIV‐1 gag/pol/nef vaccine
Trial: 23807272
Drug: Baseline risk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline risk behaviors (crack cocaine use, unprotected anal sex, drug use)
Trial: 22112610
Drug: C421A variant
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C421A variant (CA+AA versus CC) in ABCG2
Trial: 17480139
Drug: Quyu Xiaoban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quyu Xiaoban capsules (QYXB) plus aspirin (300 mg loading dose, 100 mg maintenance dose) for 4 weeks
Trial: 17480139
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg loading dose, 100 mg maintenance dose) for 4 weeks
Trial: 15228130
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide 5%/clindamycin 1% gel (BP/C)
Trial: 11754710
Drug: Rofecoxib, 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib, 12.5 mg/d
Trial: 11754710
Drug: Celecoxib, 200
RxNorm normalized name: Celecoxib, 200 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib, 200 mg/d
Trial: 11754710
Drug: Acetaminophen, 4000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen, 4000 mg/d
Trial: 6658629
Drug: Cefoxitin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (2 g intramuscularly)
Trial: 6658629
Drug: Penicillin (4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin (4.8 X 10(6) units aqueous procaine penicillin G intramuscularly)
Trial: 15910834
Drug: Chloramphenicol ointment
RxNorm normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloramphenicol ointment applied at the surgical site at the end of procedure and 3rd day postoperatively
Trial: 15910834
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no chloramphenicol ointment)
Trial: 7977145
Drug: Milk chocolate
RxNorm normalized name: Meritene Milk Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk chocolate (280 g/d or 10 oz/d)
Trial: 7977145
Drug: Milk chocolate
RxNorm normalized name: Meritene Milk Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk chocolate (46.2 g or 1.65 oz)
Trial: 165862
Drug: Neutral red
RxNorm normalized name: neutral red
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral red photodynamic inactivation treatment
Trial: 23680854
Drug: Manual-guided psychodynamic
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual-guided psychodynamic therapy
Trial: 20113526
Drug: Snoezelen therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Snoezelen therapy
Trial: 20113526
Drug: Structured reminiscence
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured reminiscence therapy
Trial: 16614415
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g sesame seed powder daily for 5 weeks
Trial: 11129729
Drug: Paclitaxel (Taxol)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (Taxol) at escalating doses starting from 100 mg/m2 up to 250 mg/m2; Cremophor EL starting dose of 8.3 ml/m2 with increments of 2.1 ml/m2; Carboplatin dosages of 300, 350, or 400 mg/m2.
Trial: 8793497
Drug: GnRH analogue
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH analogue (goserelin) + oral contraceptive (OC) containing ethinyl estradiol and cyproterone acetate
Trial: 8793497
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (OC) containing ethinyl estradiol and cyproterone acetate
Trial: 1546145
Drug: moclobemide 150-150-150
RxNorm normalized name: moclobemide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moclobemide 150-150-150 mg
Trial: 1546145
Drug: toloxatone 400-200-400
RxNorm normalized name: toloxatone
DrugBank: Toloxatone (DB09245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: toloxatone 400-200-400 mg
Trial: 2689470
Drug: Meptazinol 50
RxNorm normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol 50 mg
Trial: 6615689
Drug: Meptazinol 200
RxNorm normalized name: meptazinol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol 200 mg
Trial: 3987183
Drug: Morphine 16
RxNorm normalized name: morphine sulfate 16 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 16 mg
Trial: 27792719
Drug: Maggot debridement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maggot debridement therapy (MDT)
Trial: 20676860
Drug: Topical lanolin
RxNorm normalized name: lanolin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lanolin ointment (PureLan)
Trial: 20676860
Drug: Bovine type
RxNorm normalized name: Bovine type I collagen
DrugBank: Bovine type I collagen (DB10771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine type I collagen spray (Gelfix)
Trial: 24691853
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no topical treatment)
Trial: 18565251
Drug: Intra-articular hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular hyaluronic acid (HA) injections (3 injections with one-week interval)
Trial: 18565251
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (6 weeks)
Trial: 12236885
Drug: 3% 2-dimethylaminoethanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% 2-dimethylaminoethanol (DMAE) gel
Trial: 12236885
Drug: Control formulation
RxNorm normalized name: nut.tx, weight loss-control formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control formulation without DMAE
Trial: 7536438
Drug: Intradermal recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal recombinant human TNF-alpha (rHuTNF-alpha) 100 U (group A)
Trial: 7536438
Drug: Intradermal recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal recombinant human TNF-alpha (rHuTNF-alpha) 5000 U (group B)